Pharmaceutical Technology Europe
It is very difficult to measure the problem of counterfeiting accurately from year to year; by definition criminals don?t file tax returns or publish quarterly earnings.
Mark Davison
Advertisement
Mark Davison is CEO at Blue Sphere Health Ltd and the author of Pharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs and Pharmaceutical Serialisation: Opportunity or Perfect Storm.www.bluespherehealth.com
Articles by Mark Davison
Pharmaceutical Technology Europe
The effects of counterfeiting are hard to measure, both in human impact and financial loss.
Pharmaceutical Technology Europe
The effects of counterfeiting are hard to measure, both in human impact and financial loss.
Advertisement
Latest Updated Articles
Applying Universal Anticounterfeiting TechnologiesNovember 1st 2011
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5